Skip to content

3D Systems

US · DDD #3666 by market cap Listed 2011
1.35 -0.13 -8.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership rose 5.2 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
81.49% +5.17pp
Institutions
245 -1
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund48.11%
Hedge Fund23.09%
Public Company5.73%
Individual/Insider3.42%
Insurance Company1.66%
Private Company1.65%
Family Office/Trust1.16%
Other15.08%

Top holders as of 2026-09-30

BlackRock 8.75% · 14.55M sh
State Street Global Advisors 8.13% · 13.53M sh
Aigh Capital Management, LLC 4.88% · 8.12M sh
Vanguard Capital Management, LLC 4.20% · 6.98M sh
Two Sigma Investments, LP 3.94% · 6.56M sh
The Bank of Nova Scotia 3.15% · 5.25M sh
D. E. Shaw & Co., L.P. 2.56% · 4.26M sh
Marshall Wace LLP 2.36% · 3.93M sh
Geode Capital Management, LLC 2.13% · 3.54M sh
Needham Investment Management, LLC 2.12% · 3.53M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 22 buys · 28 sells

NameRoleStake
Jeffrey Graves Chief Executive Officer 0.74%
Phyllis Nordstrom Executive VP, CFO & Chief Administrative Officer 0.43%
Jim Kever Independent Director 0.34%
Charles Hull Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus 0.31%
Reji Puthenveetil Executive VP of Additive Solutions & Chief Commercial Officer 0.29%
Thomas Erickson Independent Director 0.24%
Kevin Moore Independent Director 0.19%
Joseph Zuiker Executive Vice President of Engineering & Operations 0.16%
Charles McClure Independent Chairperson 0.14%
John Tracy Independent Director 0.14%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-16 Jeffrey Graves Chief Executive Officer Open Market Disposition -42,686 $3.55
2026-09-16 Phyllis Nordstrom Executive VP, CFO & Chief Administrative Officer Open Market Disposition -30,000 $3.58
2026-09-07 Charles Hull Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus Sale to Issuer -4,943 $3.38
2026-09-07 Jeffrey Graves Chief Executive Officer Sale to Issuer -39,959 $3.38
2026-09-07 Phyllis Nordstrom Executive VP, CFO & Chief Administrative Officer Sale to Issuer -47,396 $3.38
2026-09-07 Andrew Wright Senior VP of General Counsel & Corporate Secretary Sale to Issuer -5,818 $3.38
2026-09-07 Reji Puthenveetil Executive VP of Additive Solutions & Chief Commercial Officer Sale to Issuer -15,984 $3.38
2026-09-07 Joseph Zuiker Executive Vice President of Engineering & Operations Sale to Issuer -6,689 $3.38
2026-08-19 Jeffrey Graves Chief Executive Officer Open Market Disposition -115,500 $3.26
2026-05-13 Jim Kever Independent Director Other Acquisition +45,731 --
2026-05-13 Thomas Erickson Independent Director Other Acquisition +45,731 --
2026-05-13 Kevin Moore Independent Director Other Acquisition +45,731 --
2026-05-13 Charles McClure Independent Chairperson Other Acquisition +45,731 --
2026-05-13 John Tracy Independent Director Other Acquisition +45,731 --
2026-05-13 Malissia Clinton Independent Director Other Acquisition +45,731 --
2026-05-13 Vasant Padmanabhan Independent Director Other Acquisition +45,731 --
2026-05-13 Claudia Drayton Independent Director Other Acquisition +45,731 --
2026-04-13 Charles Hull Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus Sale to Issuer -4,102 $1.98
2026-04-13 Jeffrey Graves Chief Executive Officer Sale to Issuer -30,500 $1.98
2026-04-13 Phyllis Nordstrom Executive VP, CFO & Chief Administrative Officer Sale to Issuer -1,626 $1.98

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:35 · For reference only, not investment advice and not tailored to your situation.

3D Systems discussion 0 comments

Add a comment